Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 09:34
01/20/22
01/20
09:34
01/20/22
09:34
AGEN

Agenus

$2.82 /

-0.035 (-1.23%)

, AZN

AstraZeneca

$59.46 /

-0.37 (-0.62%)

, BAYRY

Bayer

$14.82 /

+0.13 (+0.88%)

, BMY

Bristol-Myers

$64.73 /

-0.175 (-0.27%)

, CRDF

Cardiff Oncology

$4.54 /

-1.585 (-25.88%)

, DSNKY

Daiichi Sankyo

$22.44 /

-0.5385 (-2.34%)

, DCPH

Deciphera

$8.50 /

+0.225 (+2.72%)

, DNA

Ginkgo Bioworks

$5.04 /

-0.25 (-4.73%)

, ESALY

Eisai

$52.17 /

-0.39 (-0.74%)

, EXAS

Exact Sciences

$76.09 /

-1.24 (-1.60%)

, EXEL

Exelixis

$17.09 /

-0.28 (-1.61%)

, GH

Guardant Health

$71.99 /

-0.48 (-0.66%)

, HCM

Hutchmed

$29.71 /

-0.76 (-2.49%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.81 /

-0.19 (-0.25%)

, IPSEY

Ipsen

$24.15 /

+0.4145 (+1.75%)

, LLY

Eli Lilly

$245.08 /

-2.075 (-0.84%)

, MRK

Merck

$81.30 /

-0.25 (-0.31%)

, MRTX

Mirati Therapeutics

$120.93 /

+4.85 (+4.18%)

, NTRA

Natera

$61.27 /

+0.14 (+0.23%)

, NVCR

Novocure

$64.11 /

-0.37 (-0.57%)

, NVS

Novartis

$88.85 /

-0.7 (-0.78%)

, ORIC

Oric Pharmaceuticals

$11.72 /

-0.13 (-1.10%)

, PBLA

Panbela Therapeutics

$1.68 /

-0.06 (-3.45%)

, PFE

Pfizer

$53.54 /

-0.58 (-1.07%)

, SGEN

Seagen

$132.55 /

+2.2 (+1.69%)

, TPTX

Turning Point Therapeutics

$36.57 /

+0.44 (+1.22%)

, VCYT

Veracyte

$27.23 /

-0.54 (-1.94%)

, ZYME

Zymeworks

$13.44 /

+0.055 (+0.41%)

ASCO Gastrointestinal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$52.17 /

-0.39 (-0.74%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$71.99 /

-0.48 (-0.66%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.81 /

-0.19 (-0.25%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$61.27 /

+0.14 (+0.23%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$64.11 /

-0.37 (-0.57%)

07:49 Today Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
06:15 Today Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$88.85 /

-0.7 (-0.78%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$132.55 /

+2.2 (+1.69%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
11/15/21 Roth Capital
Turning Point fundamentals strong heading into 2022, says Roth Capital
VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

Hot Stocks
Merck's Keytruda combination featured in published Phase 3 study in carcinoma » 06:54
01/20/22
01/20
06:54
01/20/22
06:54
MRK

Merck

$81.30 /

-0.25 (-0.31%)

, ESALY

Eisai

$52.17 /

-0.39 (-0.74%)

Merck (MRK) and Eisai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$81.30 /

-0.25 (-0.31%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
ESALY Eisai
$52.17 /

-0.39 (-0.74%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

Recommendations
Neurocrine price target lowered to $100 from $110 at Barclays » 06:31
01/20/22
01/20
06:31
01/20/22
06:31
NBIX

Neurocrine

$72.82 /

-1.63 (-2.19%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Neurocrine to $100 from $110 and keeps an Overweight rating on the shares ahead of the company's Q4 results. Large-cap biotech is "at a crossroads ahead of near-term catalysts," Gould tells investors in a research note.

ShowHide Related Items >><<
NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

01/18/22 RBC Capital
Neurocrine cut to Sector Perform at RBC Capital on fewer catalysts in 2022
01/18/22 RBC Capital
Neurocrine downgraded to Sector Perform from Outperform at RBC Capital
12/08/21 Raymond James
Raymond James sees 10% rally today for Neurocrine on Ingrezza data
12/08/21 Oppenheimer
Neurocrine price target raised to $154 from $140 at Oppenheimer
NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

NBIX Neurocrine
$72.82 /

-1.63 (-2.19%)

Yesterday
Hot Stocks
Xenon Pharmaceuticals' flunarizine granted FDA orphan designation » 17:58
01/19/22
01/19
17:58
01/19/22
17:58
XENE

Xenon Pharmaceuticals

$31.54 /

+0.7 (+2.27%)

According to a post on…

According to a post on the FDA's website, Xenon Pharmaceuticals' treatment of juvenile absence epilepsy, flunarizine, was granted orphan designation. Reference Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$31.54 /

+0.7 (+2.27%)

XENE Xenon Pharmaceuticals
$31.54 /

+0.7 (+2.27%)

11/11/21 SVB Leerink
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
XENE Xenon Pharmaceuticals
$31.54 /

+0.7 (+2.27%)

  • 06
    Oct
  • 10
    Mar
XENE Xenon Pharmaceuticals
$31.54 /

+0.7 (+2.27%)

On The Fly
Wall Street in Fives - Must Read Lists for Wednesday » 16:29
01/19/22
01/19
16:29
01/19/22
16:29
BAC

Bank of America

$46.45 /

+0.09 (+0.19%)

, MS

Morgan Stanley

$95.74 /

+1.625 (+1.73%)

, ZGNX

Zogenix

$25.91 /

+10.27 (+65.66%)

, SOFI

SoFi Technologies

$13.71 /

+1.67 (+13.87%)

, DIS

Disney

$150.15 /

-2.15 (-1.41%)

, CSCO

Cisco

$58.91 /

-0.85 (-1.42%)

, LVS

Las Vegas Sands

$43.92 /

+0.82 (+1.90%)

, KBH

KB Home

$43.38 /

-1.82 (-4.03%)

, LEN

Lennar

$96.87 /

-4.36 (-4.31%)

, ZBH

Zimmer Biomet

$123.29 /

-2.965 (-2.35%)

, GO

Grocery Outlet

$25.01 /

-0.44 (-1.73%)

, KSS

Kohl's

$51.84 /

+2.085 (+4.19%)

, GS

Goldman Sachs

$347.29 /

-6.915 (-1.95%)

, BHP

BHP Group

$68.51 /

+2.08 (+3.13%)

, SU

Suncor

$28.38 /

-0.22 (-0.77%)

, PTON

Peloton

$31.85 /

+1.62 (+5.36%)

, SBUX

Starbucks

$96.85 /

-0.89 (-0.91%)

, FREY

Freyr Battery

$9.70 /

+1.075 (+12.47%)

, HON

Honeywell

$210.66 /

-2.89 (-1.35%)

, TTWO

Take-Two

$163.30 /

+9.34 (+6.07%)

, UL

Unilever

$50.02 /

+3.56 (+7.66%)

, PLUG

Plug Power

$20.99 /

-1.84 (-8.06%)

, GSK

GlaxoSmithKline

$45.68 /

-1.14 (-2.43%)

, CFG

Citizens Financial

$54.35 /

-1.32 (-2.37%)

, PG

Procter & Gamble

$161.98 /

+5.12 (+3.26%)

, FAST

Fastenal

$58.06 /

-0.3 (-0.51%)

, USB

U.S. Bancorp

$57.38 /

-4.825 (-7.76%)

, UNH

UnitedHealth

$462.66 /

+1.43 (+0.31%)

, CMA

Comerica

$96.76 /

-2.69 (-2.70%)

Get caught up quickly on…

ShowHide Related Items >><<
ZGNX Zogenix
$25.91 /

+10.27 (+65.66%)

ZBH Zimmer Biomet
$123.29 /

-2.965 (-2.35%)

USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

UL Unilever
$50.02 /

+3.56 (+7.66%)

TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

SU Suncor
$28.38 /

-0.22 (-0.77%)

SOFI SoFi Technologies
$13.71 /

+1.67 (+13.87%)

SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

PTON Peloton
$31.85 /

+1.62 (+5.36%)

PLUG Plug Power
$20.99 /

-1.84 (-8.06%)

PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

MS Morgan Stanley
$95.74 /

+1.625 (+1.73%)

LVS Las Vegas Sands
$43.92 /

+0.82 (+1.90%)

LEN Lennar
$96.87 /

-4.36 (-4.31%)

KSS Kohl's
$51.84 /

+2.085 (+4.19%)

KBH KB Home
$43.38 /

-1.82 (-4.03%)

HON Honeywell
$210.66 /

-2.89 (-1.35%)

GSK GlaxoSmithKline
$45.68 /

-1.14 (-2.43%)

GS Goldman Sachs
$347.29 /

-6.915 (-1.95%)

GO Grocery Outlet
$25.01 /

-0.44 (-1.73%)

FREY Freyr Battery
$9.70 /

+1.075 (+12.47%)

FAST Fastenal
$58.06 /

-0.3 (-0.51%)

DIS Disney
$150.15 /

-2.15 (-1.41%)

CSCO Cisco
$58.91 /

-0.85 (-1.42%)

CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

BHP BHP Group
$68.51 /

+2.08 (+3.13%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

01/12/22 Citi
Citi opens '30-Day Positive Catalyst Watch' on Bank of America
01/11/22 Piper Sandler
Bank of America the large cap bank stock to own for 2022, says Piper Sandler
01/06/22 JPMorgan
Bank of America price target raised to $52.50 from $50 at JPMorgan
01/05/22 Societe Generale
Bank of America downgraded to Hold at Societe Generale on expensive valuation
MS Morgan Stanley
$95.74 /

+1.625 (+1.73%)

01/03/22 Barclays
Morgan Stanley price target raised to $123 from $110 at Barclays
12/03/21
Fly Intel: Top five analyst upgrades
12/03/21 Citi
Morgan Stanley upgraded to Buy from Neutral at Citi
10/18/21 Citi
Morgan Stanley price target raised to $105 from $100 at Citi
ZGNX Zogenix
$25.91 /

+10.27 (+65.66%)

01/19/22 Stifel
UCB acquisition 'a great outcome' for Zogenix, says Stifel
01/19/22 JMP Securities
Zogenix downgraded to Market Perform from Outperform at JMP Securities
01/19/22 William Blair
Zogenix downgraded to Market Perform from Outperform at William Blair
01/19/22 Needham
Zogenix downgraded to Hold from Buy at Needham
SOFI SoFi Technologies
$13.71 /

+1.67 (+13.87%)

01/19/22 Rosenblatt
SoFi Technologies price target raised to $30 at Rosenblatt after bank charter
01/19/22 Mizuho
SoFi Technologies news 'significant positive catalyst,' says Mizuho
01/19/22 Citi
SoFi Technologies bank approval should be positive catalyst, says Citi
01/18/22 Wedbush
Wedbush starts SoFi at Outperform on 'strong' growth outlook
DIS Disney
$150.15 /

-2.15 (-1.41%)

01/18/22 MoffettNathanson
Disney price target lowered to $165 from $175 at MoffettNathanson
01/14/22 Guggenheim
Disney downgraded to Neutral at Guggenheim on slower profit climb
01/14/22 Wedbush
Apple pursuing sports content would be 'right move at right time,' says Wedbush
01/14/22 JPMorgan
Disney remains top pick in media at JPMorgan
CSCO Cisco
$58.91 /

-0.85 (-1.42%)

01/19/22 Goldman Sachs
Cisco downgraded to Neutral from Buy at Goldman Sachs
01/18/22 KeyBanc
Cisco transferred with Overweight at KeyBanc
01/11/22 BofA
Juniper double-upgraded to Buy from Underperform at BofA
01/07/22 Tigress Financial
Cisco shares going to $73 in 12 months, says Tigress Financial
LVS Las Vegas Sands
$43.92 /

+0.82 (+1.90%)

01/19/22 UBS
Las Vegas Sands upgraded to Buy at UBS on new Macau gaming legislation
01/19/22 UBS
Las Vegas Sands upgraded to Buy from Neutral at UBS
01/18/22 Citi
Las Vegas Sands price target raised to $60 from $57 at Citi
01/16/22 Goldman Sachs
Las Vegas Sands upgraded to Conviction Buy from Buy at Goldman Sachs
KBH KB Home
$43.38 /

-1.82 (-4.03%)

01/19/22 UBS
KB Home initiated with a Buy at UBS
01/19/22 KeyBanc
KB Home downgraded to Underweight from Sector Weight at KeyBanc
01/14/22 Seaport Global
KB Home downgraded to Neutral from Buy at Seaport Global
01/14/22 Raymond James
KB Home price target raised to $63 from $55 at Raymond James
LEN Lennar
$96.87 /

-4.36 (-4.31%)

01/19/22 UBS
Lennar initiated with a Buy at UBS
01/19/22 KeyBanc
Lennar downgraded to Underweight from Sector Weight at KeyBanc
01/14/22 Seaport Global
Lennar upgraded to Buy from Neutral at Seaport Global
ZBH Zimmer Biomet
$123.29 /

-2.965 (-2.35%)

01/19/22 Wells Fargo
Wells Fargo downgrades Zimmer Biomet to Underweight, lowers target to $124
01/19/22 Wells Fargo
Zimmer Biomet downgraded to Underweight from Overweight at Wells Fargo
01/10/22 BTIG
Zimmer Biomet downgraded to Neutral from Buy at BTIG
01/07/22 Morgan Stanley
Zimmer Biomet cut to Equal Weight at Morgan Stanley on procedure disruption
GO Grocery Outlet
$25.01 /

-0.44 (-1.73%)

01/19/22 BofA
Grocery Outlet downgraded to Underperform from Neutral at BofA
01/19/22 BofA
Grocery Outlet downgraded to Underperform from Neutral at BofA
11/02/21 Deutsche Bank
Grocery Outlet price target lowered to $29 from $32 at Deutsche Bank
08/11/21
Fly Intel: Top five analyst downgrades
KSS Kohl's
$51.84 /

+2.085 (+4.19%)

01/07/22 UBS
Kohl's downgraded to Sell from Neutral at UBS
01/04/22 JPMorgan
Kohl's price target lowered to $55 from $73 at JPMorgan
01/03/22 Guggenheim
Nike remains a 'Best Idea' at Guggenheim heading into 2022
11/19/21 Jefferies
Kohl's price target raised to $75 at Jefferies on higher margin likelihood
GS Goldman Sachs
$347.29 /

-6.915 (-1.95%)

06:18 Today Citi
Goldman Sachs price target lowered to $455 from $480 at Citi
01/19/22 Barclays
Goldman Sachs price target lowered to $505 from $556 at Barclays
01/19/22 BMO Capital
Goldman Sachs price target lowered to $448 from $455 at BMO Capital
01/19/22 Oppenheimer
Goldman Sachs price target lowered to $574 from $598 at Oppenheimer
BHP BHP Group
$68.51 /

+2.08 (+3.13%)

01/19/22 Gordon Haskett
Gordon Haskett notes Nutrien previously a target of BHP after Bloomberg report
01/14/22 Barclays
BHP Group price target raised to 2,350 GBp from 2,000 GBp at Barclays
12/09/21 Morgan Stanley
Rio Tinto upgraded to Overweight at Morgan Stanley after underperformance
10/20/21 Jefferies
Jefferies downgrades trio of iron ore miners on near-term downside risk
SU Suncor
$28.38 /

-0.22 (-0.77%)

01/13/22 Scotiabank
Suncor price target raised to C$38 from C$37 at Scotiabank
01/10/22 BofA
Suncor reinstated with a Buy at BofA
01/10/22 BofA
Suncor reinstated with a Buy at BofA
01/06/22 National Bank
Suncor price target raised to C$45 from C$39 at National Bank
PTON Peloton
$31.85 /

+1.62 (+5.36%)

01/18/22 JMP Securities
Peloton price raise could bring $150M in fiscal 2023 sales, says JMP Securities
01/14/22 Loop Capital
Peloton price target lowered to $90 from $110 at Loop Capital
01/07/22 KeyBanc
KeyBanc cautious on Peloton margins after new Bike+, Tread promotions
01/05/22 JPMorgan
Peloton price target lowered to $50 from $70 at JPMorgan
SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

01/18/22 BofA
Starbucks' loyalty program trends suggest robust demand growth, says BofA
01/07/22 Oppenheimer
Oppenheimer downgrades Starbucks on lack of earnings upside potential
01/07/22 RBC Capital
RBC downgrades Starbucks on balanced risk/reward profile
01/07/22 RBC Capital
Starbucks downgraded to Sector Perform from Outperform at RBC Capital
FREY Freyr Battery
$9.70 /

+1.075 (+12.47%)

01/04/22 Morgan Stanley
Ferrari replacing GM as Morgan Stanley's new 'Top Pick' in U.S. autos
12/17/21 Piper Sandler
Freyr Battery initiated with a Neutral at Piper Sandler
11/18/21 JPMorgan
Freyr Battery initiated with a Neutral at JPMorgan
10/12/21 Credit Suisse
Freyr Battery initiated with an Outperform at Credit Suisse
HON Honeywell
$210.66 /

-2.89 (-1.35%)

01/14/22 Berenberg
Honeywell initiated with a Hold at Berenberg
01/07/22 UBS
Honeywell upgraded to Buy from Neutral at UBS
01/07/22 UBS
Honeywell upgraded to Buy from Neutral at UBS
01/04/22 JPMorgan
Honeywell price target lowered to $265 from $275 at JPMorgan
TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

01/19/22 BTIG
Zynga downgraded to Neutral from Buy at BTIG
01/19/22 Exane BNP Paribas
Take-Two upgraded to Outperform from Neutral at Exane BNP Paribas
01/19/22 Deutsche Bank
Activision Blizzard downgraded to Hold from Buy at Deutsche Bank
01/18/22 Truist
Activision Blizzard downgraded to Hold from Buy at Truist
UL Unilever
$50.02 /

+3.56 (+7.66%)

01/19/22 Societe Generale
Societe Generale double upgrades Unilever after selloff on 'clumsy' bid
01/19/22 Societe Generale
Unilever upgraded to Buy from Sell at Societe Generale
01/17/22 Bernstein
Unilever downgraded to Underperform from Market Perform at Bernstein
01/17/22 Barclays
Unilever downgraded to Equal Weight from Overweight at Barclays
PLUG Plug Power
$20.99 /

-1.84 (-8.06%)

01/13/22 Morgan Stanley
Clean Tech industry view upgraded to Attractive at Morgan Stanley
01/11/22 Citi
Plug Power price target lowered to $37 from $56 at Citi
01/05/22 KeyBanc
Plug Power initiated with an Overweight at KeyBanc
11/20/21 Citi
Citi initiates pair trade of Overweight Plug Power, Underweight Ballard Power
GSK GlaxoSmithKline
$45.68 /

-1.14 (-2.43%)

01/19/22 Citi
Procter & Gamble unlikely to bid for GSK unit, says Citi
CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

01/13/22 UBS
Citizens Financial initiated with a Neutral at UBS
01/13/22 Morgan Stanley
NatWest Group, SVB Financial added as top bank picks at Morgan Stanley
01/11/22 Citi
Citizens Financial upgraded to Buy with $65 target at Citi
01/11/22 Citi
Citizens Financial upgraded to Buy from Neutral at Citi
PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

10/20/21 Deutsche Bank
Procter & Gamble price target lowered to $160 from $163 at Deutsche Bank
10/19/21 Stifel
Procter & Gamble Q1 results 'solid' amid added cost headwinds, says Stifel
10/05/21
Fly Intel: Top five analyst initiations
FAST Fastenal
$58.06 /

-0.3 (-0.51%)

12/07/21 Loop Capital
Fastenal price target raised to $57 from $53 at Loop Capital
12/07/21 Baird
Fastenal price target raised to $62 from $59 at Baird
10/08/21 Wells Fargo
Wells downgrades Fastenal to Underweight on 'multiple emerging risks'
10/08/21 Wells Fargo
Fastenal downgraded to Underweight from Equal Weight at Wells Fargo
USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

01/19/22 Keefe Bruyette
U.S. Bancorp downgraded to Market Perform from Outperform at Keefe Bruyette
01/03/22 Barclays
U.S. Bancorp downgraded to Equal Weight from Overweight at Barclays
12/09/21 UBS
UBS starts 'not so boring' U.S. Bancorp at Buy
12/09/21 UBS
U.S. Bancorp initiated with a Buy at UBS
UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

01/11/22 Bernstein
UnitedHealth price target raised to $564 from $508 at Bernstein
01/10/22 Edward Jones
UnitedHealth initiated with a Buy at Edward Jones
01/05/22 Truist
UnitedHealth price target raised to $575 from $520 at Truist
01/04/22 Piper Sandler
Nevro shares should rally on UnitedHealthcare coverage, says Piper Sandler
CMA Comerica
$96.76 /

-2.69 (-2.70%)

01/12/22 B. Riley
Comerica price target raised to $100 from $87 at B. Riley
01/07/22 Baird
Baird downgrades Comerica to sell after 'euphoric price action'
01/07/22 Baird
Comerica downgraded to Underperform from Neutral at Baird
01/06/22 BofA
Comerica upgraded to Neutral from Underperform at BofA
ZGNX Zogenix
$25.91 /

+10.27 (+65.66%)

ZBH Zimmer Biomet
$123.29 /

-2.965 (-2.35%)

USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

SU Suncor
$28.38 /

-0.22 (-0.77%)

SOFI SoFi Technologies
$13.71 /

+1.67 (+13.87%)

SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

PTON Peloton
$31.85 /

+1.62 (+5.36%)

PLUG Plug Power
$20.99 /

-1.84 (-8.06%)

PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

MS Morgan Stanley
$95.74 /

+1.625 (+1.73%)

LVS Las Vegas Sands
$43.92 /

+0.82 (+1.90%)

LEN Lennar
$96.87 /

-4.36 (-4.31%)

KSS Kohl's
$51.84 /

+2.085 (+4.19%)

KBH KB Home
$43.38 /

-1.82 (-4.03%)

HON Honeywell
$210.66 /

-2.89 (-1.35%)

GSK GlaxoSmithKline
$45.68 /

-1.14 (-2.43%)

GS Goldman Sachs
$347.29 /

-6.915 (-1.95%)

GO Grocery Outlet
$25.01 /

-0.44 (-1.73%)

FREY Freyr Battery
$9.70 /

+1.075 (+12.47%)

FAST Fastenal
$58.06 /

-0.3 (-0.51%)

DIS Disney
$150.15 /

-2.15 (-1.41%)

CSCO Cisco
$58.91 /

-0.85 (-1.42%)

CMA Comerica
$96.76 /

-2.69 (-2.70%)

CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

  • 16
    Nov
  • 16
    Nov
  • 27
    Jan
USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

UL Unilever
$50.02 /

+3.56 (+7.66%)

TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

SU Suncor
$28.38 /

-0.22 (-0.77%)

SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

PTON Peloton
$31.85 /

+1.62 (+5.36%)

PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

MS Morgan Stanley
$95.74 /

+1.625 (+1.73%)

LVS Las Vegas Sands
$43.92 /

+0.82 (+1.90%)

LEN Lennar
$96.87 /

-4.36 (-4.31%)

KSS Kohl's
$51.84 /

+2.085 (+4.19%)

KBH KB Home
$43.38 /

-1.82 (-4.03%)

HON Honeywell
$210.66 /

-2.89 (-1.35%)

GSK GlaxoSmithKline
$45.68 /

-1.14 (-2.43%)

GS Goldman Sachs
$347.29 /

-6.915 (-1.95%)

DIS Disney
$150.15 /

-2.15 (-1.41%)

CSCO Cisco
$58.91 /

-0.85 (-1.42%)

CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

BHP BHP Group
$68.51 /

+2.08 (+3.13%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

ZBH Zimmer Biomet
$123.29 /

-2.965 (-2.35%)

USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

SOFI SoFi Technologies
$13.71 /

+1.67 (+13.87%)

SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

PLUG Plug Power
$20.99 /

-1.84 (-8.06%)

PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

LEN Lennar
$96.87 /

-4.36 (-4.31%)

KSS Kohl's
$51.84 /

+2.085 (+4.19%)

KBH KB Home
$43.38 /

-1.82 (-4.03%)

HON Honeywell
$210.66 /

-2.89 (-1.35%)

FAST Fastenal
$58.06 /

-0.3 (-0.51%)

DIS Disney
$150.15 /

-2.15 (-1.41%)

CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

BHP BHP Group
$68.51 /

+2.08 (+3.13%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

ZGNX Zogenix
$25.91 /

+10.27 (+65.66%)

USB U.S. Bancorp
$57.38 /

-4.825 (-7.76%)

UNH UnitedHealth
$462.66 /

+1.43 (+0.31%)

TTWO Take-Two
$163.30 /

+9.34 (+6.07%)

SU Suncor
$28.38 /

-0.22 (-0.77%)

SOFI SoFi Technologies
$13.71 /

+1.67 (+13.87%)

SBUX Starbucks
$96.85 /

-0.89 (-0.91%)

PTON Peloton
$31.85 /

+1.62 (+5.36%)

PLUG Plug Power
$20.99 /

-1.84 (-8.06%)

PG Procter & Gamble
$161.98 /

+5.12 (+3.26%)

MS Morgan Stanley
$95.74 /

+1.625 (+1.73%)

LVS Las Vegas Sands
$43.92 /

+0.82 (+1.90%)

LEN Lennar
$96.87 /

-4.36 (-4.31%)

KSS Kohl's
$51.84 /

+2.085 (+4.19%)

KBH KB Home
$43.38 /

-1.82 (-4.03%)

HON Honeywell
$210.66 /

-2.89 (-1.35%)

GSK GlaxoSmithKline
$45.68 /

-1.14 (-2.43%)

GS Goldman Sachs
$347.29 /

-6.915 (-1.95%)

FREY Freyr Battery
$9.70 /

+1.075 (+12.47%)

DIS Disney
$150.15 /

-2.15 (-1.41%)

CSCO Cisco
$58.91 /

-0.85 (-1.42%)

CMA Comerica
$96.76 /

-2.69 (-2.70%)

CFG Citizens Financial
$54.35 /

-1.32 (-2.37%)

BHP BHP Group
$68.51 /

+2.08 (+3.13%)

BAC Bank of America
$46.45 /

+0.09 (+0.19%)

Hot Stocks
Sangamo CEO says preclinical studies moving forward 'beautifully' » 13:59
01/19/22
01/19
13:59
01/19/22
13:59
SGMO

Sangamo

$6.12 /

+0.19 (+3.20%)

, TAK

Takeda Pharmaceutical

$14.42 /

-0.13 (-0.89%)

, BIIB

Biogen

$233.23 /

-0.47 (-0.20%)

, NVS

Novartis

$89.11 /

-0.435 (-0.49%)

, GILD

Gilead

$69.54 /

-0.89 (-1.26%)

Sangamo Therapeutics…

Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, CEO Sandy Macrae talked about the company's preclinical studies: "Everything is moving forward beautifully. Until we get to the IND, we tend to keep the cards close to our chest on the benefits of our programs. But related to the TX200, which is the renal transplant subject, we have TREG programs being developed in multiple sclerosis for example. In our CNS portfolio, we have very interesting assets in important neurological diseases moving forward and closer to clinic. We will publish results on them during the year. It takes time. We're an unusual company with such a broad and deep portfolio, and a pipeline that keeps on giving and it's all due to our technology which can be applied to so many areas of unmet medical need. And we also have our partnerships with Biogen [BIIB] for Alzheimer's and Parkinson's disease, which is making great progress; our work we are doing with Novartis [NVS] on Autism spectrum disorder, which again is moving forward; with Takeda [TAK] for Huntington's; and with Kite [GILD] and their oncology program. They are all moving forward and getting closer and closer to the IND, which is when investors and analysts really start getting interested in it," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.42 /

-0.13 (-0.89%)

SGMO Sangamo
$6.12 /

+0.19 (+3.20%)

NVS Novartis
$89.11 /

-0.435 (-0.49%)

GILD Gilead
$69.54 /

-0.89 (-1.26%)

BIIB Biogen
$233.23 /

-0.47 (-0.20%)

SGMO Sangamo
$6.12 /

+0.19 (+3.20%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
TAK Takeda Pharmaceutical
$14.42 /

-0.13 (-0.89%)

01/13/22 Goldman Sachs
Takeda Pharmaceutical downgraded to Neutral from Buy at Goldman Sachs
10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
BIIB Biogen
$233.23 /

-0.47 (-0.20%)

01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
NVS Novartis
$89.11 /

-0.435 (-0.49%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
GILD Gilead
$69.54 /

-0.89 (-1.26%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
SGMO Sangamo
$6.12 /

+0.19 (+3.20%)

NVS Novartis
$89.11 /

-0.435 (-0.49%)

GILD Gilead
$69.54 /

-0.89 (-1.26%)

BIIB Biogen
$233.23 /

-0.47 (-0.20%)

TAK Takeda Pharmaceutical
$14.42 /

-0.13 (-0.89%)

NVS Novartis
$89.11 /

-0.435 (-0.49%)

GILD Gilead
$69.54 /

-0.89 (-1.26%)

BIIB Biogen
$233.23 /

-0.47 (-0.20%)

TAK Takeda Pharmaceutical
$14.42 /

-0.13 (-0.89%)

SGMO Sangamo
$6.12 /

+0.19 (+3.20%)

NVS Novartis
$89.11 /

-0.435 (-0.49%)

GILD Gilead
$69.54 /

-0.89 (-1.26%)

BIIB Biogen
$233.23 /

-0.47 (-0.20%)

TAK Takeda Pharmaceutical
$14.42 /

-0.13 (-0.89%)

NVS Novartis
$89.11 /

-0.435 (-0.49%)

GILD Gilead
$69.54 /

-0.89 (-1.26%)

BIIB Biogen
$233.23 /

-0.47 (-0.20%)

Hot Stocks
Sangamo COO sees three 'important catalysts' over next 12 months » 13:51
01/19/22
01/19
13:51
01/19/22
13:51
SGMO

Sangamo

$6.17 /

+0.24 (+4.05%)

, PFE

Pfizer

$53.67 /

-0.45 (-0.83%)

, BMRN

BioMarin

$87.00 /

+0.33 (+0.38%)

, SNY

Sanofi

$52.09 /

-0.07 (-0.13%)

Sangamo Therapeutics…

Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, COO Mark McClung discussed the company's upcoming data readouts: "We think we have three really important catalysts coming up over the course of the next 12 months. The first is related to our partner program with Pfizer [PFE], which is the Hemophilia A program and is in Phase 3. We're anticipating that the clinical hold put on by Pfizer and the agency will be lifted shortly and we will continue to advance the enrollment in that trial. At this point, we're still confident we will have a competitive profile versus the BioMarin [BMRN] product. The second would be our Fabry disease program. We shared the promising preliminary proof of concept Phase 1/2 data from the first two dosing cohorts back at our Q3 results but since then we've dosed a fifth patient in the high dose third cohort and have line of sight on the six cohort and we've initiated Phase 3 planning. Over the course of 2022, you can expect additional data presentations which will provide the update on the patients. We will most likely share some of that in an upcoming congress. And additionally, there are two sets of information we're hoping to be able to comment on through the end of the year. The first is related to the fact that of the four patients we showed at our Q3 release, two of those patients were on enzyme replacement therapy and for one of those patients - patient four - we already started the withdrawal of the enzyme replacement therapy and we will have the data to see what happens. That patient will still have the benefit of the gene therapy. For the second patient, which was the first patient enrolled in the trial, we're getting consent to do the same thing. Additionally, in the third cohort - so patients 5 and 6 - we've done baseline kidney biopsies and we're hoping that throughout the course of the year, but most likely towards the end of the year, we'll be able to provide a perspective on the impact on the lyso-Gb3 disposition on the kidney. Very excited over that program, particularly in the context of the recent changes in the landscape competitive. We believe that the profile of our Fabry gene therapy program is shaping up very nicely. We're excited about that program which is currently wholly own. Lastly, related to the sickle cell program which has been in the hands of Sanofi [SNY]... Sanofi made a strategic decision as part of its genomics medicine strategy to get out of personalized medicines, including personalized cell therapy - so, we're in the midst of a six-month transition period with them. There are four patients left to dose, which we've committed with Sanofi to complete by the early Q3 of this year. But what's important is these next four patients will be dosed using a new manufacturing. Additionally, the TX200 kidney transplant study with our TX200 compound, which is a CAR-TREG, is the first we believe in human trial with CAR-TREGs. We've enrolled the first patient in the trial and are expecting to dose the first two patients by the middle of 2022," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

ShowHide Related Items >><<
SNY Sanofi
$52.09 /

-0.07 (-0.13%)

SGMO Sangamo
$6.17 /

+0.24 (+4.05%)

PFE Pfizer
$53.67 /

-0.45 (-0.83%)

BMRN BioMarin
$87.00 /

+0.33 (+0.38%)

SGMO Sangamo
$6.17 /

+0.24 (+4.05%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
PFE Pfizer
$53.67 /

-0.45 (-0.83%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
BMRN BioMarin
$87.00 /

+0.33 (+0.38%)

01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
01/09/22 Piper Sandler
Piper Sandler bullish on BioMarin as Roctavian looks 'commercially compelling'
01/07/22 Truist
BioMarin price target raised to $135 from $125 at Truist
01/04/22 Piper Sandler
BioMarin raised prices across commercial portfolio, says Piper Sandler
SNY Sanofi
$52.09 /

-0.07 (-0.13%)

01/06/22 UBS
Sanofi price target raised to EUR 117 from EUR 116 at UBS
12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/21/21 Roth Capital
Sanofi deal for Amunix 'hints at' value of Harpoon platforms, says Roth Capital
SNY Sanofi
$52.09 /

-0.07 (-0.13%)

SGMO Sangamo
$6.17 /

+0.24 (+4.05%)

PFE Pfizer
$53.67 /

-0.45 (-0.83%)

BMRN BioMarin
$87.00 /

+0.33 (+0.38%)

SNY Sanofi
$52.09 /

-0.07 (-0.13%)

PFE Pfizer
$53.67 /

-0.45 (-0.83%)

SNY Sanofi
$52.09 /

-0.07 (-0.13%)

SGMO Sangamo
$6.17 /

+0.24 (+4.05%)

PFE Pfizer
$53.67 /

-0.45 (-0.83%)

BMRN BioMarin
$87.00 /

+0.33 (+0.38%)

PFE Pfizer
$53.67 /

-0.45 (-0.83%)

Recommendations
UCB acquisition 'a great outcome' for Zogenix, says Stifel » 13:51
01/19/22
01/19
13:51
01/19/22
13:51
ZGNX

Zogenix

$26.05 /

+10.405 (+66.53%)

Stifel analyst Paul…

Stifel analyst Paul Matteis believes UCB's acquisition of Zogenix is a favorable outcome for shareholders and ascribes a good deal of value for Fintepla's potential in Dravet with optionality in Lennox-Gastaut syndrome, or LGS. With the stock having been well off its highs, Matteis was optimistic that Zogenix could have created value independently, but the path was more linear/gradual via proving out continued penetration in Dravet, Fintepla's approvability in LGS, and that the drug still has a role in LGS despite average efficacy versus other AEDs in that indication. From a deal perspective, the analyst believes the majority of the $2/share contingent value right should be priced into the stock as he thinks LGS approval in the EU is likely. While he thinks a competitive bid is not impossible, it is "probably unlikely" as UCB with Vimpat going off patent was always one of the most logical acquirers of Zogenix. Matteis has a Buy rating on Zogenix shares.

ShowHide Related Items >><<
ZGNX Zogenix
$26.05 /

+10.405 (+66.53%)

ZGNX Zogenix
$26.05 /

+10.405 (+66.53%)

01/19/22 JMP Securities
Zogenix downgraded to Market Perform from Outperform at JMP Securities
01/19/22 William Blair
Zogenix downgraded to Market Perform from Outperform at William Blair
01/19/22 Needham
Zogenix downgraded to Hold from Buy at Needham
01/19/22 Guggenheim
Zogenix downgraded to Neutral from Buy at Guggenheim
ZGNX Zogenix
$26.05 /

+10.405 (+66.53%)

ZGNX Zogenix
$26.05 /

+10.405 (+66.53%)

ZGNX Zogenix
$26.05 /

+10.405 (+66.53%)

Downgrade
Zogenix downgraded to Market Perform from Outperform at JMP Securities » 13:50
01/19/22
01/19
13:50
01/19/22
13:50
ZGNX

Zogenix

/

+

JMP Securities analyst…

JMP Securities analyst Jason Butler downgraded Zogenix to Market Perform from Outperform after UCB agreed to acquire all outstanding shares for $26 per share in cash at closing, plus one non-tradeable contingent value right for a potential cash payment of $2 per share.

ShowHide Related Items >><<
ZGNX Zogenix
/

+

ZGNX Zogenix
/

+

01/19/22 William Blair
Zogenix downgraded to Market Perform from Outperform at William Blair
01/19/22 Needham
Zogenix downgraded to Hold from Buy at Needham
01/19/22 Guggenheim
Zogenix downgraded to Neutral from Buy at Guggenheim
01/19/22 Northland
Zogenix price target lowered to $26 from $32 at Northland
ZGNX Zogenix
/

+

ZGNX Zogenix
/

+

ZGNX Zogenix
/

+

On The Fly
Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung » 13:32
01/19/22
01/19
13:32
01/19/22
13:32
SGMO

Sangamo

$6.18 /

+0.25 (+4.22%)

, BIIB

Biogen

$234.15 /

+0.45 (+0.19%)

, PFE

Pfizer

$53.83 /

-0.29 (-0.54%)

, TAK

Takeda Pharmaceutical

$14.44 /

-0.11 (-0.76%)

, GILD

Gilead

$69.71 /

-0.72 (-1.02%)

, BMRN

BioMarin

$87.35 /

+0.68 (+0.78%)

, NVS

Novartis

$89.28 /

-0.27 (-0.30%)

In an exclusive interview…

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.44 /

-0.11 (-0.76%)

SGMO Sangamo
$6.18 /

+0.25 (+4.22%)

PFE Pfizer
$53.83 /

-0.29 (-0.54%)

NVS Novartis
$89.28 /

-0.27 (-0.30%)

GILD Gilead
$69.71 /

-0.72 (-1.02%)

BMRN BioMarin
$87.35 /

+0.68 (+0.78%)

BIIB Biogen
$234.15 /

+0.45 (+0.19%)

SGMO Sangamo
$6.18 /

+0.25 (+4.22%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
03/03/21 Wells Fargo
Sangamo price target lowered to $29 from $36 at Wells Fargo
BIIB Biogen
$234.15 /

+0.45 (+0.19%)

06:31 Today Barclays
Biogen price target lowered to $244 from $280 at Barclays
01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
PFE Pfizer
$53.83 /

-0.29 (-0.54%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
TAK Takeda Pharmaceutical
$14.44 /

-0.11 (-0.76%)

01/13/22 Goldman Sachs
Takeda Pharmaceutical downgraded to Neutral from Buy at Goldman Sachs
10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
GILD Gilead
$69.71 /

-0.72 (-1.02%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
BMRN BioMarin
$87.35 /

+0.68 (+0.78%)

01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
01/09/22 Piper Sandler
Piper Sandler bullish on BioMarin as Roctavian looks 'commercially compelling'
01/07/22 Truist
BioMarin price target raised to $135 from $125 at Truist
01/04/22 Piper Sandler
BioMarin raised prices across commercial portfolio, says Piper Sandler
NVS Novartis
$89.28 /

-0.27 (-0.30%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
SGMO Sangamo
$6.18 /

+0.25 (+4.22%)

PFE Pfizer
$53.83 /

-0.29 (-0.54%)

NVS Novartis
$89.28 /

-0.27 (-0.30%)

GILD Gilead
$69.71 /

-0.72 (-1.02%)

BMRN BioMarin
$87.35 /

+0.68 (+0.78%)

BIIB Biogen
$234.15 /

+0.45 (+0.19%)

TAK Takeda Pharmaceutical
$14.44 /

-0.11 (-0.76%)

PFE Pfizer
$53.83 /

-0.29 (-0.54%)

NVS Novartis
$89.28 /

-0.27 (-0.30%)

GILD Gilead
$69.71 /

-0.72 (-1.02%)

BIIB Biogen
$234.15 /

+0.45 (+0.19%)

TAK Takeda Pharmaceutical
$14.44 /

-0.11 (-0.76%)

SGMO Sangamo
$6.18 /

+0.25 (+4.22%)

PFE Pfizer
$53.83 /

-0.29 (-0.54%)

NVS Novartis
$89.28 /

-0.27 (-0.30%)

GILD Gilead
$69.71 /

-0.72 (-1.02%)

BMRN BioMarin
$87.35 /

+0.68 (+0.78%)

BIIB Biogen
$234.15 /

+0.45 (+0.19%)

TAK Takeda Pharmaceutical
$14.44 /

-0.11 (-0.76%)

PFE Pfizer
$53.83 /

-0.29 (-0.54%)

NVS Novartis
$89.28 /

-0.27 (-0.30%)

GILD Gilead
$69.71 /

-0.72 (-1.02%)

BIIB Biogen
$234.15 /

+0.45 (+0.19%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.